Iohexol is a non-ionic, low-osmolar, water-soluble iodinated contrast medium used for intravascular and intrathecal radiographic procedures. The 300 mg Iodine/mL concentration is a standard strength for various diagnostic imaging studies. It provides excellent radiographic contrast with a favorable safety profile due to its low osmolality, reducing the risk of adverse reactions compared to older ionic agents.
Adult: Dose is highly variable and depends on procedure, patient weight, and imaging modality. Examples: CT of body: 50-150 mL (15-45g I); Angiography: Varies by vessel; Myelography: 10-15 mL (3-4.5g I). The 300 mg I/mL strength is commonly used for CT, IVP, and angiography.
Note: For intravascular use: Administer as a bolus injection or controlled infusion using a power injector for CT. Strict aseptic technique. Warm to body temperature if large volume. For intrathecal use: MUST be preservative-free formulation only. Administered via lumbar puncture under strict aseptic conditions by trained specialist. Patient must remain with head elevated post-procedure.
Iohexol is a radiopaque contrast agent. It contains iodine atoms (47% by weight) which effectively absorb X-rays. When introduced into body cavities, vessels, or the subarachnoid space, it attenuates X-rays to a greater degree than surrounding tissues, creating a contrast difference that allows visualization of anatomical structures and functional assessment (e.g., blood flow, patency) on radiographic or CT images.
Pregnancy: Category B. Iodinated contrast agents cross the placenta. Use only if clearly needed and potential benefit justifies potential risk to the fetus. Fetal thyroid function may be affected if used during the second or third trimester.
Driving: Patients may experience dizziness or vasovagal reactions. They should be advised not to drive or operate machinery until these effects have completely resolved, typically on the same day after the procedure.
| Metformin | Risk of lactic acidosis if contrast-induced nephropathy occurs. Must withhold metformin prior to and after procedure per protocol. | High |
| Interleukin-2 (IL-2) | Increased risk of delayed hypersensitivity reactions to contrast media. | Moderate |
| Beta-blockers (e.g., Propranolol) | May blunt response to treatment of anaphylactoid reactions (e.g., to epinephrine) and increase risk of bronchospasm. | Moderate |
| NSAIDs (e.g., Ibuprofen) | May potentiate nephrotoxic effects, increasing risk of CIN. | Moderate |
| Diuretics (e.g., Furosemide) | May increase risk of nephrotoxicity and dehydration. | Moderate |
Same composition (Iohexol (300mg)), different brands: